Luk Vandenberghe

CEO, Associate Professor 
​ciendias bio

Luk H. Vandenberghe, PhD is a scientist, engineer and entrepreneur in the fields of gene therapy and vaccines. He is on leave from his positions as the Grousbeck Family Chair in Gene Therapy at Mass Eye and Ear (Mass General Brigham), Associate Professor at Harvard Medical School and Associate Member of the Broad Institute of Harvard and MIT in Boston, MA, USA while he is building a novel vaccine platform startup biotech company. His previous work led to the key scientific findings and the discovery of core technologies in use in clinical genetic medicine today.  Dr. Vandenberghe previously co-founded GenSight Biologics, Akouos (now part of Lilly), Odylia and Affinia Therapeutics.  He serves on the board of Affinia Therapeutics and ciendias bio as well as two non-profit boards Odylia Therapeutics and Addgene. Dr. Vandenberghe has over 100 peer reviewed publications and more than a dozen licensed patents.